Eli Lilly and Comp. (LLY) Stock Forecast for 2024–2028. Sell or Buy Prediction







6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?

At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…

Eli Lilly and Comp. (LLY) Stock Forecast for 2024–2028. Sell or Buy?

Updated: March 28, 2024 (08:38)

Sector: Healthcare

The share price of Eli Lilly and Company (LLY) now

Latest session on the 27th of March for
Eli Lilly and Company is positive
Trading Volume: 2297713
Open: 778.71 /  High: 785.26 /  Low: 767.38
What analysts predict: $809.74
52-week High/Low: $800.78 / $333.28

50/200 Day Moving Average: $725.05 / $589.55

This figure corresponds to the Average Price over the previous 50/200 days. For Eli Lilly and Comp. stocks, the 50-day moving average is the support level today.

For Eli Lilly and Comp. stocks, the 200-day moving average is the support level today.

Are you interested in Eli Lilly and Company stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Eli Lilly and Comp. stock price in 2024, 2025, 2026, 2027, 2028. How much will one Eli Lilly and Comp. share be worth in 2024 - 2028?

When should I take profit in Eli Lilly and Comp. stock? When should I record a loss on Eli Lilly and Comp. stock? What are analysts' forecasts for Eli Lilly and Comp. stock? What is the future of Eli Lilly and Comp. stock? We forecast Eli Lilly and Comp. stock performance using neural networks based on historical data on Eli Lilly and Comp. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Eli Lilly and Comp. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Eli Lilly and Comp. shares. This happens once a day.


Historical and forecast chart of Eli Lilly and Comp. stock

The chart below shows the historical price of Eli Lilly and Comp. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Eli Lilly and Comp. stock price can be found in the table below.

Long-term forecasts by years.

Eli Lilly's Stock Forecast: Riding the Wave of Innovation

Trend: Bullish
Mar 23, 2024

When it comes to assessing the future trajectory of Eli Lilly and Comp. (LLY) stock, several critical elements stand out, poised to shape its course in the near term. The blend of traditional drug revenues and the exploration of new growth markets are key factors in painting an accurate LLY stock forecast. Understanding these dynamics can offer insightful clues for those wondering whether LLY stock is a buy or sell.

Decoding Key Influencers on LLY Stock Rates

At the heart of LLY's potential for sustained growth is its robust portfolio of traditional drugs, which analysts bank on to grow impressively. This foundational strength is crucial, not just for its inherent value but for its reliability in generating a consistent cash flow. This aspect alone could be a robust argument for considering LLY a good stock to buy, thanks to its expected growth rate of 14% until the 10th year, widening to a 3% growth trajectory thereafter.

Beyond the core, the future sparkles with potential emanating from new growth markets. Eli Lilly's strategic pursuits in the obesity, Alzheimer's, psoriasis, and diabetes Type I markets could significantly elevate its stock price prediction. Analysts eyeing the LLY stock price target find these markets attractive due to their vast potential and Lilly's proactive stance, including noteworthy acquisitions, which could revolutionize its market footprint.

Understanding how these factors interplay is pivotal for any analyst aiming to craft a well-rounded Eli Lilly and Comp. stock forecast. The blending of stable growth from existing products with the explosive potential of new markets offers a compelling narrative. For investors deciphering whether to buy or sell Eli Lilly and Comp. stock, the message seems clear: the party is not over for LLY, with innovation and market expansions acting as critical levers for its future success.

  • Traditional drug revenues
  • New growth markets impact:
    • Obesity market
    • Alzheimer's market
    • Psoriasis market
    • Diabetes Type I market

In sum, the interplay of these factors presents a promising outlook for LLY's stock rate changes, making it an attractive option for investors seeking growth in a dynamically evolving healthcare landscape.

Review the original Analysis
About author

Unlocking the Future: The Path to Predicting LLY Stocks

Trend: Bullish
Mar 18, 2024

When diving into the volatile world of stock markets, one ticker that catches the eye is LLY—Eli Lilly and Comp. This pharmaceutical giant has been a hot topic among analysts, particularly due to its groundbreaking work in obesity treatment. The LLY stock forecast is a complex puzzle, intricately tied to several pivotal factors that could sway its rate in the near future.

The Blueprint to LLY's Stock Trajectory

At the forefront, the efficacy and market reception of Zepbound, Eli Lilly's flagship obesity treatment drug, plays a crucial role. Since Zepbound has already surpassed its competitors in terms of new prescriptions, its continued acceptance and success are pivotal for those considering LLY stock as a good buy. Furthermore, developments within Eli Lilly's clinical pipelines, especially the progress of orforglipron and other Phase 1 candidates, stand out as significant indicators. The impact of competition cannot be understated, with Novo Nordisk's CagriSema nipping at Zepbound's heels. This competitive landscape shapes a crucial question—is LLY stock a buy or sell?

To navigate these waters, analysts lean heavily on real-world data and clinical trial outcomes. Understanding the market's reception of Zepbound, coupled with progress in Eli Lilly’s pipeline, can guide analysts in making the most accurate LLY stock price prediction. It's a dynamic balance of forecasting the potential market shifts and weighing the competition's progress.

  • Efficacy and market reception of Zepbound
  • Clinical developments and pipeline progress
  • Competition with Novo Nordisk and others

With these factors in play, savvy investors and analysts will find themselves in a thrilling race to predict the future of LLY stocks. Will they choose to buy, sell, or hold? Only time—and diligent analysis—will tell.

Review the original Analysis
About author

Unraveling the Future of LLY Stock: A Predictive Guide

Trend: Bearish
Feb 20, 2024

When it comes to forecasting the twists and turns of Eli Lilly's (LLY) stock prices, a trio of pivotal factors stand out, poised to shape the near future. Firstly, the recent retail buying and options frenzy, fueled by media hype and speculative interest, has catapulted LLY stock into the stratosphere. This surge, though thrilling, whispers warnings of a potential bubble waiting to burst. Secondly, the phenomenon of short covering, where short sellers rush to buy back shares to cover their positions, has further propelled the stock upwards. However, this movement is more reflective of a tactical retreat rather than genuine bullish sentiment. Lastly, the looming specter of valuation and overvaluation cannot be ignored. Currently standing at a towering 83x earnings, LLY's valuation significantly overshadows that of its pharmaceutical brethren, casting doubts on its sustainability.

Deciphering Stock Movements: Analysts at Work

An astute analyst would meticulously scrutinize these factors, extracting insights for precise stock movement predictions. The crux lies in balancing the heady optimism around retail buying with the hard figures of valuation. By keeping a pulse on the transition from speculative buying to potential selling, and analyzing the ripple effects of short covering, an analyst can sketch a comprehensive forecast. Equipped with a nuanced understanding of these dynamics, they can navigate the speculative ebbs and flows, steering away from the mirage of overvaluation towards more grounded predictions.

In essence, the immediate future of LLY’s stock rate is a tapestry woven from speculative fervor, forced buying actions, and valuations straining credulity. Parsing these threads could reveal the intricate patterns of future movements, presenting an analytical challenge as thrilling as it is complex.

Review the original Analysis
About author

Eli Lilly and Company is an American pharmaceutical company. It was founded in 1876 in Indianapolis, Indiana, where its headquarters are still located. It is known as the first company to start the industrial production of insulin (in 1923). The company operates in two areas: medicines for humans and veterinary medicines (a division of Elanco). The company’s products are sold in 120 countries.

www.lilly.com

Eli Lilly and Comp. daily forecast for a month

Date Target Pes. Opt. Vol., %
Mar 30 769.78 757.31 781.56 3.20
Mar 31 767.47 760.79 776.45 2.06
Apr 01 772.77 766.97 778.56 1.51
Apr 02 776.94 771.35 791.16 2.57
Apr 03 772.74 760.23 787.35 3.57
Apr 04 775.99 768.31 793.68 3.30
Apr 05 767.84 754.02 784.66 4.06
Apr 06 761.62 754.31 773.73 2.57
Apr 07 761.17 748.15 777.38 3.91
Apr 08 767.79 753.05 786.21 4.40
Apr 09 776.77 758.59 792.85 4.52
Apr 10 795.41 783.96 812.12 3.59
Apr 11 795.41 789.45 809.02 2.48
Apr 12 796.61 785.61 801.86 2.07
Apr 13 811.18 806.07 826.52 2.54
Apr 14 819.46 805.69 828.31 2.81
Apr 15 834.70 817.92 848.22 3.70
Apr 16 829.94 815.00 840.15 3.09
Apr 17 813.76 801.31 829.87 3.56
Apr 18 818.40 800.47 830.67 3.77
Apr 19 819.38 803.89 829.46 3.18
Apr 20 828.47 811.82 836.43 3.03
Apr 21 846.62 836.71 858.30 2.58
Apr 22 837.47 830.44 854.56 2.90
Apr 23 850.29 841.36 856.92 1.85
Apr 24 839.57 824.71 853.18 3.45
Apr 25 826.48 813.34 841.11 3.41
Apr 26 827.96 814.30 836.66 2.75
Apr 27 817.04 803.31 822.43 2.38
Apr 28 806.01 794.64 821.72 3.41

Eli Lilly and Comp. Daily Price Targets


Eli Lilly and Comp. Stock Forecast 03-30-2024.

Forecast target price for 03-30-2024: $769.78.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.103%.
Pessimistic target level: 757.31
Optimistic target level: 781.56

Eli Lilly and Comp. Stock Forecast 03-31-2024.

Forecast target price for 03-31-2024: $767.47.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.016%.
Pessimistic target level: 760.79
Optimistic target level: 776.45

Eli Lilly and Comp. Stock Forecast 04-01-2024.

Forecast target price for 04-01-2024: $772.77.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 1.489%.
Pessimistic target level: 766.97
Optimistic target level: 778.56

Eli Lilly and Comp. Stock Forecast 04-02-2024.

Forecast target price for 04-02-2024: $776.94.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.504%.
Pessimistic target level: 771.35
Optimistic target level: 791.16

Eli Lilly and Comp. Stock Forecast 04-03-2024.

Forecast target price for 04-03-2024: $772.74.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.445%.
Pessimistic target level: 760.23
Optimistic target level: 787.35

Eli Lilly and Comp. Stock Forecast 04-04-2024.

Forecast target price for 04-04-2024: $775.99.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.197%.
Pessimistic target level: 768.31
Optimistic target level: 793.68

LLY (LLY) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Apr. 818.65 739.89 864.41 14.40
May. 793.10 715.78 815.79 12.26
Jun. 748.77 700.10 788.68 11.23
Jul. 780.89 718.97 813.38 11.61
Aug. 698.66 642.35 726.82 11.62
Sep. 662.33 637.36 712.27 10.52
Oct. 692.47 632.16 748.28 15.52
Nov. 736.58 687.74 800.74 14.11
Dec. 779.67 728.99 800.95 8.98

Eli Lilly and Comp. forecast for this year


Eli Lilly and Comp. Stock Prediction for Apr 2024

An uptrend is forecast for this month with an optimal target price of $818.645. Pessimistic: $739.89. Optimistic: $864.41


Eli Lilly and Comp. Stock Prediction for May 2024

An downtrend is forecast for this month with an optimal target price of $793.104. Pessimistic: $715.78. Optimistic: $815.79


Eli Lilly and Comp. Stock Prediction for Jun 2024

An downtrend is forecast for this month with an optimal target price of $748.769. Pessimistic: $700.10. Optimistic: $788.68


Eli Lilly and Comp. Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $780.891. Pessimistic: $718.97. Optimistic: $813.38


Eli Lilly and Comp. Stock Prediction for Aug 2024

An downtrend is forecast for this month with an optimal target price of $698.663. Pessimistic: $642.35. Optimistic: $726.82


Eli Lilly and Comp. Stock Prediction for Sep 2024

An downtrend is forecast for this month with an optimal target price of $662.333. Pessimistic: $637.36. Optimistic: $712.27


Eli Lilly and Comp. Stock Prediction for Oct 2024

An uptrend is forecast for this month with an optimal target price of $692.469. Pessimistic: $632.16. Optimistic: $748.28


Eli Lilly and Comp. Stock Prediction for Nov 2024

An uptrend is forecast for this month with an optimal target price of $736.579. Pessimistic: $687.74. Optimistic: $800.74


Eli Lilly and Comp. Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $779.669. Pessimistic: $728.99. Optimistic: $800.95



Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 678.31 639.51 703.89 9.15
Feb 670.38 647.72 691.29 6.30
Mar 664.28 612.46 683.27 10.36
Apr 638.37 600.19 658.29 8.82
May 675.71 630.04 694.16 9.24
Jun 653.75 634.21 675.85 6.16
Jul 711.54 644.94 752.25 14.26
Aug 701.37 682.22 746.96 8.67
Sep 678.58 611.53 703.28 13.05
Oct 667.11 619.41 691.39 10.41
Nov 657.57 600.29 705.44 14.90
Dec 628.50 609.71 657.92 7.33

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 661.19 628.52 716.20 12.24
Feb 613.91 587.57 631.47 6.95
Mar 692.12 652.53 741.61 12.01
Apr 693.02 641.67 734.47 12.63
May 650.68 583.85 710.74 17.85
Jun 629.53 595.16 672.09 11.45
Jul 648.35 585.14 709.88 17.57
Aug 594.41 557.32 613.73 9.19
Sep 524.09 496.16 567.02 12.50
Oct 556.12 539.49 573.47 5.93
Nov 553.22 517.98 605.72 14.49
Dec 544.59 498.57 559.46 10.88

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 533.27 491.67 551.98 10.93
Feb 525.64 479.86 579.62 17.21
Mar 524.27 504.51 567.89 11.16
Apr 567.21 545.83 620.30 12.01
May 605.55 578.79 628.38 7.89
Jun 585.09 526.52 620.07 15.09
Jul 621.60 597.35 640.99 6.81
Aug 630.48 595.24 694.42 14.28
Sep 630.48 592.78 659.99 10.18
Oct 670.65 629.67 704.65 10.64
Nov 634.03 602.71 660.41 8.74
Dec 602.71 562.75 623.86 9.80

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 590.17 541.07 610.12 11.32
Feb 577.90 555.36 628.23 11.60
Mar 583.91 557.34 620.34 10.16
Apr 567.21 522.96 594.49 12.03
May 617.35 584.44 642.23 9.00
Jun 677.54 624.69 713.65 12.47
Jul 683.71 664.15 733.48 9.45
Aug 650.82 615.28 671.97 8.44
Sep 625.44 596.17 656.33 9.17
Oct 631.94 574.43 658.23 12.73
Nov 637.69 574.69 676.66 15.07
Dec 686.60 666.07 727.66 8.46

Eli Lilly and Comp. information and performance

Eli Lilly and Comp. Address

LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US

Market Capitalization: 736 748 634 000 $

Market capitalization of the Eli Lilly and Company is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of LLY shares in the company outstanding by the market price of one share.

EBITDA: 12 314 600 000 $

EBITDA of Eli Lilly and Comp. is earnings before interest, income tax and depreciation of assets.

PE Ratio: 133.37

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.467

Price/earnings to growth

DPS: 4.52

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0067

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 5.81

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.13
Quarterly Revenue Growth YOY: 0.281
Trailing PE: 133.37

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 61.73

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 22.24

Enterprise Value (EV) /Revenue

EV To EBITDA: 88.59

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 950766000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Eli Lilly and Comp. (LLY) stock dividend

Eli Lilly and Comp. last paid dividends on 02/14/2024. The next scheduled payment will be on 03/08/2024. The amount of dividends is $4.52 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.